

Artificial Intelligence in transfusion medicine: a paradigm shift on the horizon

Fabrice Cognasse^{1,2}, Stéphane Avril¹, Julia L. Fleck³, Hind Hamzeh-Cognasse¹



¹INSERM, U 1059 SAINBIOSE, Université Jean Monnet, Mines Saint-Étienne, F-42023, Saint-Etienne, France;

²Etablissement Français du Sang Auvergne-Rhône-Alpes, Research Department, F-42023, Saint-Etienne, France;

³Mines Saint-Étienne, Univ Clermont Auvergne, INP Clermont Auvergne, CNRS, UMR 6158 LIMOS, Saint-Étienne, F-42023, France

INTRODUCTION

Artificial Intelligence (AI) is defined by the European Commission as referring to “systems that display intelligent behavior by analyzing their environment and taking actions –with some degree of autonomy– to achieve specific goals”¹. The integration of AI into transfusion medicine represents a revolutionary transformation in how blood products are managed, matched, and administered. AI technologies, particularly machine learning algorithms, have the potential to enhance predictive analytics, optimize donor recruitment, and ensure transfusion safety by mitigating risks associated with human error and inefficiencies. However, the application of AI in this domain raises ethical and practical concerns, including algorithmic bias, data privacy, and regulatory challenges²⁻⁶. This synthesis explores the future impact of AI on transfusion medicine, its challenges, and the future direction of research in the field (Figure 1).




Figure 1 - Overview of AI applications in transfusion medicine

The diagram illustrates the multifaceted role of artificial intelligence in enhancing transfusion medicine, highlighting key areas such as blood supply management, donor recruitment, transfusion safety, and personalized transfusion. It also addresses future perspectives, ethical challenges, and the integration of innovative technologies to optimize patient outcomes and operational efficiency.

Arrived: 2 March 2025

Revision accepted: 6 June 2025

Correspondence: Fabrice Cognasse
e-mail: fabrice.cognasse@efs.sante.fr

AI IN BLOOD SUPPLY MANAGEMENT

AI has shown promise in significantly improving blood inventory management by predicting demand fluctuations and optimizing logistics. Machine learning models have been tested to analyze seasonal patterns, demographic trends, and unexpected events such as pandemics or disasters to forecast blood needs. Preliminary AI-driven logistics systems appear to enhance the efficiency of blood collection and distribution, potentially helping to reduce geographical disparities and ensure timely deliveries^{3,4,7}. Preliminary predictive models have shown potential in determining platelet usage, which is crucial given the short shelf life of platelets. AI-based forecasting techniques have been tested and may help to minimize wastage and improve blood bank efficiency³. Moreover, early-stage AI-driven approaches to quality assessments of stored red blood cells have been explored to help clinicians evaluate the viability of blood products, with the potential to extend shelf life and enhance transfusion outcomes⁸.

ENHANCING DONOR RECRUITMENT AND RETENTION

Donor recruitment remains a key challenge in transfusion medicine, and AI offers promising, though still emerging, solutions to personalize engagement strategies. By analyzing donor behaviors and preferences, AI tools have been tested to tailor communications that may help encourage repeat donations, contributing to a stable blood supply⁶. Predictive models have shown potential to identify possible donor attrition, allowing for targeted interventions to maintain participation rates. Additionally, experimental AI applications aim to determine optimal donation times and locations, with the goal of enhancing donor convenience and increasing overall participation⁹. Moreover, early AI-driven outreach strategies appear particularly promising in diversifying the donor pool by analyzing demographic data and addressing barriers to donation. These approaches may contribute to recruiting underrepresented populations, helping to ensure a more equitable and sustainable blood supply.

IMPROVING TRANSFUSION SAFETY

AI has demonstrated promising potential in improving transfusion safety by refining donor screening and blood testing procedures. Machine learning algorithms have been tested to assess donor health records and

serological data, potentially detecting infectious risks with greater accuracy than traditional methods¹⁰. AI-powered methods for detecting transfusion-transmitted diseases are emerging as promising tools to enhance the safety of transfusion recipients^{11,12}. Additionally, experimental AI-driven tools for real-time monitoring of transfusion reactions have shown potential to enable early detection of adverse events, facilitating rapid intervention to protect patients. AI-assisted genomic approaches are being explored to enhance blood matching by reducing the risk of alloimmunization and transfusion-related complications. By integrating genetic and immunological factors into donor-recipient matching, AI may help to minimize the likelihood of transfusion reactions and improve overall patient outcomes^{3,9,13,14}.

AI AND PERSONALIZED TRANSFUSION MEDICINE

AI holds promising potential in personalizing transfusion strategies by incorporating patient-specific data, such as genetic profiles and hemoglobin trends, to determine optimal transfusion thresholds. Preliminary AI-assisted decision-support tools aim to ensure that patients receive only the necessary amount of blood, potentially reducing the risks of over-transfusion while optimizing resource utilization^{5,15-17}. Furthermore, AI is currently being explored in the development of alternative blood products, such as hemoglobin substitutes, to address challenges in blood supply and compatibility. By leveraging AI's predictive capabilities, researchers are investigating ways to enhance the safety and efficacy of manufactured blood products, which could potentially revolutionize transfusion medicine in the long term¹⁸.

CHALLENGES AND ETHICAL CONSIDERATIONS

Despite AI's transformative potential, its implementation in transfusion medicine remains limited and poses several challenges. One major concern is algorithmic bias, which can arise when AI models are trained on non-representative datasets. Such biases may reinforce disparities in patient care, leading to inequitable access to blood products and differential treatment outcomes. Ensuring diversity in AI training data is crucial for minimizing these biases and promoting equitable healthcare delivery. Another challenge lies in the limited transparency of some AI algorithms, which can make it difficult for clinicians to

fully trust AI-generated recommendations, even when they appear straightforward. This lack of interpretability, still characteristic of many current models, can undermine trust among healthcare professionals and patients². Developing explainable and clinician-oriented AI models that provide clear rationales for their recommendations is essential for fostering confidence in AI-driven transfusion practices. Data privacy and security are also critical concerns in AI applications for transfusion medicine. AI systems require access to vast amounts of sensitive patient information, raising questions about data governance and compliance with medical privacy laws². Implementing robust data protection measures, such as federated learning, has been proposed to mitigate these concerns by allowing AI models to learn from data without transferring it outside secure environments¹⁹. Moreover, the successful adoption of AI in transfusion medicine will require significant investments in infrastructure, personnel training, and regulatory frameworks. Healthcare institutions must ensure that AI technologies are gradually integrated into existing workflows while adhering to evolving legal and ethical guidelines.

FUTURE RESEARCH DIRECTIONS

As AI continues to evolve, several key research directions are emerging within transfusion medicine. One area of focus is developing AI models that minimize bias and ensure equitable care across diverse populations. Investigating strategies for protecting patient data while leveraging AI's analytical capabilities, such as federated learning, remains a critical and active area of exploration. Longitudinal and prospective studies are needed to assess the long-term impact of AI-assisted decision-making on patient outcomes and to validate the clinical utility of AI interventions. Additionally, research into the potential integration of AI into pathogen detection and blood safety measures may contribute to improving transfusion protocols²⁰. Another promising avenue is the application of AI in chronic transfusion-dependent conditions, such as sickle cell disease and thalassemia. AI-based tools are being explored for their potential to optimize transfusion schedules, which could help to improve

long-term patient care and resource allocation⁴. Furthermore, early studies suggest that AI-based strategies for personalized donor engagement, predicting donor retention patterns, and enhancing recruitment efforts warrant further validation and refinement^{5,15}.

CONCLUSIONS

The potential integration of AI in transfusion medicine holds immense promise for improving patient care, optimizing blood supply management, and enhancing transfusion safety. However, realizing AI's full potential requires a careful and ethical approach that addresses algorithmic bias, data privacy concerns, and transparency in AI decision-making. Future research should focus on refining and validating personalized transfusion strategies, developing regulatory frameworks for responsible AI implementation, and fostering interdisciplinary collaboration between transfusion specialists, AI researchers, and policymakers. By embracing these advancements while acknowledging current limitations and actively mitigating associated risks, AI has the potential to revolutionize transfusion medicine and improve healthcare outcomes for patients worldwide.

SOURCES OF SUPPORT

This work was supported by grants from the Etablissement Français du Sang, the Association "Les Amis de Rémi" Savigneux and the French "Agence Nationale de la Recherche" (National Research Agency), under grant ANR-22-CE17-0063 (project HEASY_PLAT). We are grateful to the blood donors who made this research/scientific hypothesis possible.

The Authors declare no conflicts of interest.

REFERENCES

1. European Commission. Communication from the Commission: Artificial Intelligence for Europe. Brussels, COM(2018)237 final. Available at: <https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=celex:52018DC0237>. Accessed on 25/04/2018.
2. Nagler M. Artificial Intelligence in medicine: are we ready? *Hamostaseologie*. 2024; 44(6): 422-424. doi: 10.1055/a-2443-4130.
3. Al-Riyami AZ, Gammon RR, Seheult J, Arora S, Goel R. Artificial intelligence and transfusion education, research and practice: the view from the ISBT Clinical Transfusion Working Party. *Vox Sang*. 2025. doi: 10.1111/vox.13793. [Ahead of print.]

4. Maynard S, Farrington J, Alimam S, Evans H, Li K, Wong WK, et al. Machine learning in transfusion medicine: a scoping review. *Transfusion*. 2024; 64(1): 162-184. doi: 10.1111/trf.17582.
5. Lopes MGM, Recktenwald SM, Simionato G, Eichler H, Wagner C, Quint S, et al. Big data in transfusion medicine and artificial intelligence analysis for red blood cell quality control. *Transfus Med Hemother*. 2023; 50(3): 163-173. doi: 10.1159/000530458.
6. Smit Sibinga CT. *Transfusion Medicine: from ABO to AI (Artificial Intelligence)*. In: Linwood SL, editor. Digital Health [Internet]. Brisbane (AU): Exon Publications; 2022. doi: 10.36255/exon-publications-digital-health-transfusion-medicine.
7. Chen H, Cao B, Yang J, Ren H, Xia X, Zhang X, et al. Construction and effect evaluation of prediction model for red blood cell transfusion requirement in cesarean section based on artificial intelligence. *BMC Med Inform Decis Mak*. 2023; 23(1): 213. doi: 10.1186/s12911-023-02286-1.
8. Lee SM, Lee G, Kim TK, Le T, Hao J, Jung YM, Park CW, Park JS, et al. Development and validation of a prediction model for need for massive transfusion during surgery using intraoperative hemodynamic monitoring data. *JAMA Netw Open*. 2022; 5(12): e2246637. doi: 10.1001/jamanetworkopen.2022.46637. 9.
9. Rudokaite J, Ong LS, Janssen MP, Postma E, Huis In 't Veld E. Predicting vasovagal reactions to a virtual blood donation using facial image analysis. *Transfusion*. 2022; 62(4): 838-847. doi: 10.1111/trf.16832.
10. Chang TC, Yu J, Wang Z, Hankins JS, Weiss MJ, Wu G, Westhoff CM, Chou ST, Zheng Y. Machine learning to optimize automated RH genotyping using whole-exome sequencing data. *Blood Adv*. 2024; 8(11): 2651-2659. doi: 10.1182/bloodadvances.2023011660. 11.
11. Roubinian NH, Custer B. Selected topics from the state of the science in transfusion medicine: key insights on current progress and future directions. *Transfus Med Rev*. 2023; 37(4): 150781. doi: 10.1016/j.tmr.2023.150781.
12. Li N, Pham T, Cheng C, McElfresh DC, Metcalf RA, Russell WA, Birch R, Yurkovich JT, Montemayor-Garcia C, Lane WJ, Tobian AAR, Roubinian N, Seheult J, et al. Blood demand forecasting and supply management: an analytical assessment of key studies utilizing novel computational techniques. *Transfus Med Rev*. 2023; 37(4): 150768. doi: 10.1016/j.tmr.2023.150768.
13. Wu Y, Qi H, Di Angelantonio E, Kaptoge S, Wood AM, Kim LG. Risk factors for vasovagal reactions in blood donors: a systematic review and meta-analysis. *Transfusion*. 2025; 65(1): 211-223. doi: 10.1111/trf.18078.
14. Fung MK, AuBuchon JP, Stephens LD. Classification of posttransfusion adverse events using a publicly available artificial intelligence system. *Transfusion*. 2024; 64(4): 590-596. doi: 10.1111/trf.17702.
15. Li N, Lewin A, Ning S, Waito M, Zeller MP, Tinmouth A, et al.; Canadian Transfusion Trials Group. Privacy-preserving federated data access and federated learning: improved data sharing and AI model development in transfusion medicine. *Transfusion*. 2025; 65(1): 22-28. doi: 10.1111/trf.18077.
16. Seong H, Lee KS, Choi Y, Na D, Kim J, Shin HJ, Ahn KH. Explainable artificial intelligence for predicting red blood cell transfusion in geriatric patients undergoing hip arthroplasty: machine learning analysis using national health insurance data. *Medicine (Baltimore)*. 2024; 103(8): e36909. doi: 10.1097/MD.00000000000036909.
17. Hurley NC, Schroeder KM, Hess AS. Would doctors dream of electric blood bankers? Large language model-based artificial intelligence performs well in many aspects of transfusion medicine. *Transfusion*. 2023; 63(10): 1833-1840. doi: 10.1111/trf.17526.
18. Anstey C, Ullman D, Su L, Su C, Siniard C, Simmons S, et al. The practical use of artificial intelligence in Transfusion Medicine and Apheresis. *Transfus Apher Sci*. 2024; 63(6): 104001. doi: 10.1016/j.transci.2024.104001.
19. Tschoellitsch T, Böck C, Mahečić TT, Hofmann A, Meier J. Machine learning-based prediction of massive perioperative allogeneic blood transfusion in cardiac surgery. *Eur J Anaesthesiol*. 2022; 39(9): 766-773. doi: 10.1097/eja.0000000000001721.
20. Yazer MH, Díaz-Valdés JR, Triulzi DJ, Spinella PC, Emery SP, Young PP, et al. Considering equality in transfusion medicine practice. *Br J Haematol*. 2023; 201(6): 1245-1247. doi: 10.1111/bjh.18830.